Clinical trials: Fulvestrant, completed
Metastatic Breast Cancer
Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study
The goal of this clinical trial is to learn the comparative pharmacokinetic parameters between the test product and the Reference listed drug in healthy female volunteers The main question[s] it aims to answer are: To assess the…
- Trial name
- NCT06074757
- Testing
- Fulvestrant injection
- Where
- Jordan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Healthy
Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Participants are being asked to take part in this research study to learn why growth hormone(GH) levels decline when estrogen production falls at the time of menopause.
- Trial name
- NCT01186796
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Systemic Lupus Erythematosus
Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
SLE(Systemic Lupus Erythematosus) is an autoimmune disese that primarily occurs in women(9:1 compared to men). The disease is activated by genetic and environmental factors, yet the female gender is the strongest risk factor.
- Trial name
- NCT00417430
- Testing
- ICI 182,780 (Faslodex)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
Healthy
Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
The purpose of this study is to demonstrate bioequivalence between the test drug product, fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50 mg/mL.
- Trial name
- NCT02795039
- Testing
- Fulvestrant
- Where
- 3 sites in Canada
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi
Normal Healthy Volunteers
Impact of Endogenous E2 on SSI and GH Rebound
Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release.
- Trial name
- NCT02026973
- Testing
- Fulvestrant, Anastrozole, Somatostatin
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pharmacokinetics
Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
Clinical study designed to assess the plasma pharmacokinetic profile and tolerability of Fulvestrant for Injectable Suspension after a single IM dose of Fulvestrant for Injectable Suspension compared to the reference product…
- Trial name
- NCT03324061
- Testing
- Fulvestrant for Injectable Suspension, Faslodex (Reference)
- Where
- 12 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Eagle Pharmaceuticals, Inc.